A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
Triple Negative Breast Neoplasms
DRUG: Atezolizumab|DRUG: Placebo|DRUG: Gemcitabine|DRUG: Capecitabine|DRUG: Carboplatin
Overall Survival (OS) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, OS will be tested hierarchically in the following fixed order:

* In the population with programmed deathligand 1 (PD-L1)-positive tumour status
* In the modified intent-to-treat (mITT) population, Baseline to end of study (approximately 58 months)|Overall Survival (OS) in Modified Intent-To-Treat (mITT) Popluation, OS will be tested hierarchically in the following fixed order:

* In the population with programmed deathligand 1 (PD-L1)-positive tumour status
* In the modified intent-to-treat (mITT) population, Baseline to end of study (approximately 58 months)
Proportion of Participants Alive 12 Months, Randomization to 12 months post randomization|Proportion of Participants Alive 18 Months, Randomization to 18 months post randomization|Progression-Free Survival (PFS) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.

PFS will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)|Progression-Free Survival (PFS) in mITT population, PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.

PFS will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)|Objective Response Rate (ORR) in Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|Objective Response Rate (ORR) in Modified Intent-To-Treat (mITT) Popluation, ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|Duration of Objective Response (DoR), DoR as determined by the investigator according to RECIST 1.1., Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)|Clinical Benefit Rate (CBR), CBR is defined as the proportion of participants with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1., 8 weeks for the first 12 months after treatment initiation and every 12 weeks thereafter until disease progression (through the end of study, approximately 58 months)|Confirmed Objective Response Rate (C-ORR), Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|Duration of Response for Confirmed Responders (C-DoR), Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)|Time to Confirmed Deterioration (TTD) of GHS/QoL, TTD of GHS/QoL, defined by a minimally important decrease of ≥10 points at two consecutive assessment time-points on the GHS/QoL scale (Items 29, 30) of the EORTC QLQ-C30., Baseline to end of study (approximately 58 months)|Percentage of Participants With Adverse Events, Baseline to end of study (approximately 58 months)|Maximum Serum Concentration (Cmax) of Atezolizumab, At pre-defined intervals from Day 1, Cycle 1 through Cycle 4 (cycle = 21 days)|Minimum Serum Concentration (Cmin) of Atezolizumab, At pre-defined intervals from Day 1, Cycle 1 through Cycle 4 (cycle = 21 days)|Incidence of Anti-Drug Antibodies (ADAs) to Atezolizumab, Baseline to end of study (approximately 58 months)|Relationship Between PD-L1 Protein Expression in Screening Tumour Tissue and Clinical Outcomes, Baseline to end of study (approximately 58 months)|Overall Survival (OS) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, OS will be tested hierarchically in the following fixed order:

* In the population with programmed deathligand 1 (PD-L1)-positive tumour status
* In the modified intent-to-treat (mITT) population, Baseline to end of study (approximately 58 months)|Overall Survival (OS) in mITT China Popluation, OS will be tested hierarchically in the following fixed order:

* In the population with programmed deathligand 1 (PD-L1)-positive tumour status
* In the modified intent-to-treat (mITT) population, Baseline to end of study (approximately 58 months)|Proportion of Participants Alive 12 Months in China Population, Randomization to 12 months post randomization|Proportion of Participants Alive 18 Months in China Population, Randomization to 18 months post randomization|Progression Free Survival (PFS) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.

PFS will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)|Progression Free Survival (PFS) in mITT China Population, PFS defined as the time from randomisation to the first occurrence of disease progression, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or death from any cause, whichever occurs first.

PFS will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 58 months)|Objective Response Rate (ORR) in China Population With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status, ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|ORR in Modified Intent-To-Treat (mITT) China Popluation, ORR defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1. ORR will be tested hierarchically in the following fixed order:

* In the PD-L1-positive population
* In the mITT population, Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|Duration of Objective Response (DoR) in China Population, DoR as determined by the investigator according to RECIST 1.1., Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)|Clinical Benefit Rate (CBR) in China Population, CBR is defined as the proportion of participants with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1., 8 weeks for the first 12 months after treatment initiation and every 12 weeks thereafter until disease progression (through the end of study, approximately 58 months)|Confirmed Objective Response Rate (C-ORR) in China Population, Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until disease progression, withdrawal of consent, death, or study termination (approximately 58 months)|Duration of Response for Confirmed Responders (C-DoR) in China Population, Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 58 months)|Time to Confirmed Deterioration (TTD) of GHS/QoL in China Population, TTD of GHS/QoL, defined by a minimally important decrease of ≥10 points at two consecutive assessment time-points on the GHS/QoL scale (Items 29, 30) of the EORTC QLQ-C30., Baseline to end of study (approximately 58 months)
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).